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INTRODUCTION 
 
1. HEPATOCELLULAR CARCINOMA  
 Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading 
cause of cancer mortality in the world (Ferlay J et al, 2010). The burden of cancer is 
increasing in economically developing countries as a result of population aging and 
adoption of cancer-associated lifestyle choices including smoking, physical inactivity, and 
unhealthy dietary habits. Hepatitis viral infection, food additives, alcohol, fungal toxins 
(aflatoxins), toxic industrial chemicals, air and water pollutants are the major risk factors 
of liver cancer (PaRaskevi and DePinho, 2006). HCC is seldom detected at an early stage and 
once detected treatment faces a poor prognosis in most cases (Singh P et al, 2012).  
 
1.1 EPIDEMIOLOGY   
 
Hepatocellular carcinoma (HCC) belongs to the group of epithelial cancers and represents, 
with a frequency of about 85%, the most common primary liver cancer (McKillop IH et al, 
2006). The HCC incidence may be estimated between 500.000-1.000.000 new cases for 
year, globally (Gomaa AL et al, 2008), and is characterized by a wide geographic variation; it 
ranges from less than 10 cases/100,000 in the USA and Western Europe to 50-150 
cases/100,000 in areas of Africa and Asia (Blum  HE and Spangenberg HC, 2007).  
This enormous discrepancy can be explained by the different distribution of some of the 
most important risk factors of HCC, like hepatitis B virus (HBV) infection or exposure to 
Aflatoxin B1- contaminated food, which are predominant in developing countries (Llovet 
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JM et al, 2003). Incidence of HCC is not only characterized by regional differences, but also 
by sex dependence, as the incidence in men is about twice as high as in women.  
Although the incidence of HCC rises with increasing age, reaching its peak in those aged 
above 65 years and more commonly in men (Rudolph KL. et al, 2000), over the past two 
decades there has been a shift in incidence towards a younger age group. The number of 
HCC-related deaths appears to be stabilizing, or even decreasing in some Asian 
population studies (McGlynn KA et al, 2001), a result of improved surveillance and 
treatment regimens together with aggressive HBV vaccination programmers. In contrast, 
there has been a reported increase in mortality rates in the western world, for example in 
the United States, where middle aged men in particular are most affected (El-Serag HB and 
Rudolph KL, 2007). 
 
1.2 RISK FACTORS 
Liver cirrhosis is the most common condition in the majority of cases of HCC and HBV-
related chronic hepatitis and the main cause of HCC in the world (Parkin DM et al, 2001). 
Usually HCC occurs on an established background of chronic liver disease and it rarely 
develops in a healthy liver. A number of underlying risk factors are recognized in the 
development of HCC; some are well established whilst the role of others remains 
controversial.  
1.2.1 Hepatitis B virus (HBV) 
HBV is the commonest risk factor for the development of HCC, a fact particularly relevant 
to HBV endemic areas, where vertical transmission is responsible for the majority of HBV 
acquisition (El-Serag HB and Rudolph KL, 2007). In such patients HCC can develop before the 
onset of cirrhosis as a result of the direct oncogenic effects of HBV.  
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With the increasing global implementation of HBV immunization, it is anticipated that the 
incidence of HCC will decline as a consequence of the reduced burden of HBV infection 
(Kane MA, 2003). Several factors are implicated in the pathogenesis of HBV related-HCC, 
including the chronic liver damage by HBV with necro-inflammation and consequent 
regeneration of hepatocytes. The other is the direct oncogenic property of HBV which 
integrates itself into the hepatocyte DNA, producing cis- or trans activation of cellular 
oncogenes (Liu CJ and Kao JH, 2007).  
1.2.2 Hepatitis C virus (HCV) 
Chronic HCV infection is a major risk factor for HCC development in Western European 
and North American countries (Montaldo G. et al, 2002). Usually, HCC develops after 10-20 
years of HCV infection and the increased risk is largely restricted to patients with cirrhosis 
or advanced fibrosis; the significance of HCV genotype as a risk factor for HCC is a subject 
of debate but, in a recent meta-analysis, HCV genotype 1b was implicated as key factor in 
HCC development, particularly in the context of early stage liver disease (El-Serag HB and 
Mason AC, 2000). Follow-up studies have shown that patients with combined HBV and HCV 
infection have a higher risk of developing HCC than those with HBV- or HCV alone 
(Montaldo G. et al, 2002; Sato S. et al, 1994).  
1.2.3 Aflatoxin B1 (AFB1) 
Aflatoxin B1 is a mycotoxin produced by the Aspergillus flavus and Aspergillus parasiticus 
fungi. Areas of high AFB1 exposure correspond to a high prevalence of HCC, and the 
Agency for Research on Cancer classifies it as carcinogenic compound (IARC, 1987). 
Aflatoxin B1 is metabolized to an active intermediate, AFB1-exo-8,9-epoxide, which can 
bind DNA and cause damage, and has been linked with mutations consisting in a G to T 
transversion at the third position of codon 249 of the p53 gene (249ser)(Garner RC et al, 
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1972), a common finding in HCC [Bressac B et al, 1991; Turner PC et al, 2002]. This mutation 
may be valuable as a biomarker, since it is also detectable in circulating cell-free DNA 
from the plasma, and some studies suggest that the detection of serum (249ser) months 
before the clinical diagnosis of HCC may permit early diagnosis and facilitate targeted 
treatment. Some reports suggest that the (249ser) mutation is more common in HBV-
positive tumors than in HBV-negative tumors. Indeed, it has been observed that areas 
with a high prevalence of HCC and high aflatoxin intake also correspond to areas with 
endemic HBV infection (Montaldo G et al, 2002; Groopman JD et al, 1996). 
1.2.4 Alcohol 
Prolonged heavy alcohol intake leading to cirrhosis represents one of the common and 
well established risk factors for HCC (Morgan TR et al, 2004). Recent reports demonstrate 
that ingestion of more than 80gr/day of alcohol for more than 10 years increases the risk 
o developing cancer about 5 times. On the other hand, alcohol acts as cofactor with other 
risk factors in developing countries. Positive synergism exists between alcohol intake, HBV 
and HCV infections in escalating HCC risk.  
The mechanisms by which alcohol causes HCC are incompletely understood, but it is 
hypothesized that oxidative stress, altered retinoic acid metabolism, DNA methylation, 
genetic susceptibility and decreased immune surveillance may play a role (Morgan TR et al, 
2004). 
1.2.5 Nonalcoholic fatty liver disease (NAFLD) 
NAFLD is the most common liver disorder in western countries and Japan probably as a 
result of the rise in obesity and diabetes mellitus. It occurs in the absence of alcohol 
intake, although liver histology appears consistent with alcoholic hepatitis.  
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The most serious form of NAFLD is the nonalcoholic steatohepatitis (NASH) that 
represents the hepatic manifestation of several metabolic disorders (Falck-Ytter Y et al, 
2001; Angulo P et al, 1999). NASH represents the advanced disease progression stage in the 
spectrum of NAFLD and as much as 20% of NASH may progress to cirrhosis as well as end 
stage complications such as HCC. NASH-associated HCC was reported to be linked with 
liver cirrhosis in the majority of studies (Bugianesi E. et al, 2007). The relationship between 
NASH and HCC is supported by the notion that HCC develops in patients with obesity and 
diabetes, both of them positively associated with NASH (Sanyal AJ et al, 2009). 
1.2.6 Metabolic disorders 
Obesity and diabetes are the most common metabolic disorders associated with an 
increased risk of HCC and several cancers (Calle EE at, 2003; Bianchini F et al, 2002; 
Giovannucci E et al, 2010; EL-Serag HB et al, 2006). In a cohort of 900.000 american adults, 
the risk of dying from liver cancer has been reported to be 4.5 times higher in men with a 
body mass index (BMI) ≥ 35kg/m2 or above compared to the reference group with a 
normal BMI (18.5 to 24.9 kg/m2) (Polesel j et al, 2009). A recent meta-analysis concluded 
that the summary relative risk of liver cancer was 117% for overweight subjects and 189% 
for obese individuals (Larsson SC and Wolk A, 2007). Substantial evidence indicates that also 
diabetes promotes development and progression of HCC (Giovannucci E et al, 2010; El-Serag 
HB et al, 2006). It has been demonstrated that diabetes confers a three-fold increased risk 
of HCC (Davila JA et al, 2005), and also that synergistic interactions exist between diabetes 
and other HCC risk factors (Baffy et al, 2012; Hassan MM et al, 2002).  
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1.3 DIAGNOSIS OF HEPATOCELLULAR CARCINOMA 
The European Association for Study of Liver disease (EASL) has proposed 
recommendations for the diagnosis of HCC, which are crucial for both early detection and 
the implementation of appropriate treatment. A number of different treatment 
modalities, dependent on the disease stage and offering varying prognoses, are 
recognized as possible options for the management of HCC. The concept of combining 
therapies has also been considered to improve survival. A known cirrhotic patient 
presenting a liver lesion on ultrasound >2cm in diameter has a greater than 95% chance 
of having HCC [Frazer C, 1999]. An Alpha Fetoprotein (AFP) level >200ng/ml, as well as 
radiological features consistent with HCC (e.g. hypervascularity) obtained on two dynamic 
imaging modalities such as Computerised Tomography (CT) and Magnetic Resonance 
Imaging (MRI), provides the diagnosis of HCC and negates the need for liver biopsy [Bruix 
J. et al, 2001]. Conversely, if the AFP is <200ng/mL and the characteristic vascular profile is 
not visualized on imaging, then liver biopsy is indicated to confirm the diagnosis.  
For lesions of 1-2 cm in diameter a guided liver biopsy should be performed, regardless of 
their vascular profile [Bruix J. et al, 2002]. However, it must be taken into account the 
technical difficulty of biopsying such small lesions and the discrepancy that occurs 
between pathologists in discriminating between dysplasia and well differentiated HCC. 
Thus it is arguable that lesions measuring between 1-2 cm should first be imaged with 
two dynamic studies and if the findings are not characteristic of HCC, only then proceed 
to biopsy [Bruix J. Et al, 2005]. Liver lesions smaller than 1cm in diameter are far less likely 
to be malignant in nature, especially on a background of cirrhosis and even less so if they 
fail to take up contrast on dynamic imaging [Iwasaki M. et al, 1998].  
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However, the potential for malignant transformation of even tiny nodules over time still 
remains [Fracanzani AL. Et al, 2001; Takayama T. et al, 1990] and it is therefore prudent to 
continue ultrasound follow-up every 3-6 months in order to prevent HCC development 
[Bruix J. Et al, 2005]. A lack of increase in size over a period greater than 1-2 years permits 
return to the routine surveillance programme [Bruix J. Et al, 2005]. Comparing different 
tumour markers for early HCC diagnosis, AFP had a sensitivity of 66% and specificity of 
81%, at a new cut off of 10.9 ng/mL [Marrero JA, et al, 2009]. The serum biomarkers Protein 
Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) and glypican-3 (GPC3) have 
recently been assayed in patients with HCC (Beale G et al, 2008). The clinical or 
symptomatic phase of HCC is characterized by the occurrence of symptoms caused by the 
tumor burden. In patients with chronic liver disease, HCC usually becomes symptomatic 
when it reaches a size of 4.5-8cm (Yuen MF et al, 2000; Trevisani F. et al, 2002).  
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1.4 GENETIC AND EPIGENETIC EVENTS IN HEPATOCARCINOGENESIS 
Hepatocarcinogenesis is a very complex multistep process whereby HCC development 
correlate the presence of chronic liver damage, and only rarely occurs in individuals with 
healthy liver. Cirrhosis  is the predisposing condition to the development of HCC, which is 
diagnosed after about 20-40 years of latency. The aim of current research studies is to 
understand the molecular basis of hepatocarcinogenesis, namely the genetic and 
epigenetic changes that occur during the stages of initiation, promotion and progression 
of the pathology (Aravalli RN, 2008; El Serag HB and Rudolph KL, 2007). In a setting of chronic 
inflammation, the organ microenvironment experiences a variety of molecular changes 
(Grisham JV, 2001; Bosh FX et al, 1999; Buendia MA, 2000).  
In liver, cytokines and reactive oxygen and nitrogen species produced by inflammatory 
cells have been shown to mediate liver damage and induce the liver’s regenerative 
response. This predisposes the proliferating cell to a variety of changes at the genomic 
and transcriptional levels, increases the risk of genetic mutations in hepatocytes and 
promotes survival and expansion of initiated cells (Levrero M, 2006; Maeda S, 2010; He G and 
Karin M, 2011). Additionally, reactive oxygen species (ROS) and nitrogen oxygen species 
(NOS), generated by both “initiated” and infiammatory cells, could accelerate 
hepatocarcinogenesis through several mechanisms such as the induction of oxidative 
DNA damage, aberrant DNA methylation, and ultimately hepatocyte injury (He G and Karin 
M, 2011).        
Large-scale quantitative comparisons of HCC with non-tumoral tissue by the use of 
comparative genomic hybridization (CGH) arrays and loss of heterozygosity (LOH) analysis 
have revealed the occurrence of chromosomal and microsatellite instability in HCC 
subtypes (Wilkens L et al, 2000; Chen YJ et al, 2000).  
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The most frequently deleted chromosomes arms are 1p, 4q, 6q, 8p, 9p, 13q, 16p, 16q and 
17p and regional gains are most often observed in 1q, 6p, 8q and 17q (Thorgeirsson SS and 
Grisham JW, 2002; Homayounfar K et al, 2009), which, in general correspond to autosome 
arms that contain allelic deletions identified by LOH: 1p, 1q, 4q, 5q, 6q, 8p, 9p, 13q, 16p, 
16q and 17p [Thorgeirsson SS and Grisham JW, 2002; Homayounfar K et al, 2009; Laurent-Puig P 
et al, 2001]. Regardless of tumor size, individual HCCs can present multiple allelic deletions 
and chromosomal gains and losses, which can accumulate during successive cell 
proliferation events and result in a heterogeneous mixture of genomic aberrations.  
The heterogeneity of tumors can help to identify tumor origin and, due to the sensitivity 
of CGH and single nucleotide polymorphism (SNP) arrays, genomic alterations can be 
used as fingerprints to identify whether a tumor is a recurrent event or a second primary 
tumor [Wilkens L et al, 2000; Chen YJ et al, 2000]. The frequent loss of chromosome regions 
observed by LOH and SNP arrays has revealed the concomitant loss or mutation of tumor 
suppressor genes such as TP53 (p53), retinoblastoma (RB1) [Edamoto Y et al, 2003; 
Murakami Y et al, 1991],  CDKN2A (p16INK4A) [Laurent-Puig P et al, 2001; Liew CT et al, 1999] 
and insulin- like growth factor-2 receptor (IGF-2R) [De Souza AT et al, 1995; Oka Y et al, 2002] 
which are strongly associated with signaling pathways involved in carcinogenesis.  
The TP53 gene encodes the p53 protein which plays a pivotal role in the DNA-damage 
response network, including cell cycle arrest, apoptosis, DNA repair and cellular 
senescence. Therefore, it is not surprising that TP53 loss-of-function mutations or allelic 
deletions in chromosome 17p are commonly associated with human carcinogenesis 
[Hussain SP and Harris CC, 2006]. AFB1 is a mutagen of TP53, causing G:C to T:A 
transversions at the third base in codon 249 (converting arginine to serine) and the rate of 
TP53 249ser mutation may be accelerated in the presence of viral infection [Aguilar F et al, 
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1993; Kirk GD et al, 2005]. HBV encodes a viral protein, HBx, which can specifically bind to 
p53 and suppress p53-induced apoptosis. Strong associations have been observed 
between TP53 249ser mutation levels and HCC risk, especially with respect to primary 
tumor development and also to the interval between surgical resection and recurrence 
[Wang XW et al, 1994]. Structural genomic mutations and epigenetic changes may lead to 
altered gene expression patterns that significantly affect the signal transduction pathways 
in HCC and the resulting variability in pathway activation may be related to the cellular 
origin of HCC (Aravalli RN, 2008). 
The Wnt/β-catenin pathway is commonly known for its fundamental role in 
embryogenesis, which aids the cell in differentiation, proliferation and apoptosis (Cox RT 
and Peifer M, 1998). In the absence of Wnt signaling, cytoplasmic-β-catenin complexes with 
the tumor suppressors adenomatosis polyposis coli (APC) and Axin1, as well as the 
glycogen synthase kinase-3b (GSK-3b). In this complex, GSK-3 β phosphorylates β-catenin, 
targeting it for ubiquitination and subsequent degradation.  
In the case that Wnt signaling receptors are engaged, conformational changes in the Axin 
complex cause the release of β-catenin, which then localizes to the nucleus and activates 
the transcription of  target genes: Myc, cyclin D1 and COX2 [Chiba T et al, 2007; Clevers H 
2006; Kikuchi A, 2000]. In HCC, transcriptomic and proteomic studies have indicated an 
increase in Wnt signaling, possibly as a result of an accumulation of Axin1 mutations at 
sites that bind β-catenin and/or CTNNB1 mutations along sites marked for 
phosphorylation by GSK-3b [Yamashita T et al, 2009; Cavard C et al, 2008]. It was 
hypothesized that an increase in signaling from the Wnt pathway is necessary to maintain 
“stemness” in HCC, i.e. to sustain a subset of cells (cancer stem cells, CSC), that are 
responsible for the maintenance and growth of the tumor [Yamashita T et al, 2009].       
11 
 
Transforming growth factor-β (TGF- β) is an inflammatory cytokine implicated in an array 
of functions such as cell growth, differentiation, migration, apoptosis, adhesion, survival 
and immunity [Derynck R et al, 2001]. IGF-2R (insulin- like growth factor-2 receptor), a 
tumor suppressor gene, promotes the degradation of mitogen IGF-2 and also the 
simultaneous activation of TGF-β signaling, thereby halting cell proliferation and inhibiting 
carcinogenesis [Dennis PA and Rifkin DB, 1991]. Inflammation and subsequent genomic 
mutations in IGF-2R result in IGF-2 over-expression and a reduction in the inhibitory 
effects of TGF-b signaling, a feature commonly observed early in the development of HCC 
[El-Serag HB and Rudolph KL, 2007].  
Myc is a potent oncogene, which appears to be constitutively up-regulated in many 
human cancers, representing a phenomenon of “oncogene addiction.” Though about 30% 
of HCC cases show an up-regulation of Myc because of the Wnt/β-catenin pathway 
activation; its increased expression in HCC is also attributable to the activation of its locus 
through chromosome amplification (Wilkens L et al, 2004). One possible mechanism by 
which Myc contributes to hepatocarcinogenesis is through the induction of telomerase, 
which also appears to be active during HCC development, thereby bypassing cellular 
senescence (Wu KJ et al, 1999). Moreover, the up-regulation of Myc in a variety of tumors 
has also been associated with deregulated microRNA (miRNA) expression in many human 
malignancies, which have a significant impact on tumorigenesis and progression. On the 
other hand, the inactivation of Myc in HCC causes a subpopulation of cells to differentiate 
while the rest remain dormant, giving rise to a phenotypically diverse tumor population. 
[Kumar M et al, 2011; Reya T et al, 2001].  
PI3K/PTEN/Akt. Akt is involved in a number of biological process. The activation of the Akt 
pathway is mediated by either an activated tyrosine kinase receptor, or more rarely the 
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constitutive activation of PI3K or the loss of Phosphatase and Tensin Homolog (PTEN). 
PTEN is a tumor suppressor gene and the PTEN protein functions as a negative regulator 
of Akt. The loss of PTEN expression via a loss of heterozygosity in chromosome 10q along 
with an activation of Akt has been reported in 40%-60% of HCC cases [Hu TH et al, 2003; 
Blanco-Aparicio C et  al, 2007]. Since Akt is involved in a number of biological processes, 
such as cell survival, cell growth, apoptosis and differentiation, its deregulation has been 
implicated in many human cancers (Hu TH et al, 2003). 
Epigenetics modifications are involved in the regulation of many cellular processes 
including embryonic development, chromatin structure, X-chromosome inactivation, 
genomic imprinting and chromosome stability (Kierszenbaum AL, 2002; Okamoto I et al, 2004; 
Robertson KD, 2005). The epigenetic modifications include: DNA methylation at cytosine 
residues in CpG dinucleotides, histone tail methylation, acetylation, phosphorylation, 
ubiquitynation, sumoylation that result in alteration of chromatin structure (Pons D and 
Jukema JW, 2008). Though methylation is imperative for normal development and 
differentiation, aberrant hypomethylation at gene promoters in HCC and many human 
cancers can lead to the expression of oncogenes, or, similarly, hypermethylation can lead 
to the silencing of tumor-suppressor genes [Feltus FA et al, 2003; Miyoshi HH et al, 2004]. In 
the last decade there has been increasing evidence to support the occurrence of aberrant 
DNA methylation patterns in human HCC [Thorgeirsson SS . et al, 2002].  
In HCC, an increased expression of DNA methyltransferases (DNMTs), enzymes which 
catalyze cytosine methylation occurs early in the development of tumorigenesis. The 
frequency of aberrant DNA methylation increases from precancerous lesions to dysplastic 
nodules and finally HCC, supporting their important role in tumor progression [Wong CM. 
and Ng IO, 2008]. For instance, the tumor suppressor genes RB1 [Sakai T, et al, 1991] and 
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CDKN2A [Liew CT, et al, 1999] have been shown to be hypermethylated in HCC, leading to 
uncontrolled cell proliferation. Likewise, PTEN promoter methylation has also been 
reported in HCC, which allows the activation of the PI3K/PTEN/Akt pathway [Wang L et al, 
2007]. Epigenetic changes in HCC have also been reported at the miRNA level. Apart from 
their potential as a diagnostic tool, further understanding of methylation patterns in HCC 
may provide them useful in predicting recurrence and survival, as well [Zhang YJ, et al, 
2007].  
miRNAs in HCC. It has been established that specific miRNAs modulate various cellular 
processes in the liver and several studies revealed that the expression of miRNAs is 
deregulated in human HCC in comparison with matched non-neoplastic tissue and that 
their aberrant expression correlates with severity and poor prognosis of HCC [Murakami Y 
et al, 2006; Gramantieri L et al, 2008; Ura S et al, 2009; Calin GA et al, 2004; Huang XH et al, 
2009]. It was also found that the dysregulation of miRNAs not only is involved in tumor 
progression, but it is also associated with the role of risk factors directly involved in tumor 
development, as demonstrated by the discovery that HBV and HCV induce different sets 
of miRNAs during infection [Nordenstedt H et al, 2010; Ura S et al, 2009]. Although changes in 
the expression of microRNAs between tumor specimens and the normal corresponding 
tissue have been investigated in HCC as well, the obtained results are often discordant 
and do not allow the identification of the miRNAs critical for development and 
progression of HCC. Furthermore, among the microRNAs whose expression has changed, 
several are probably altered not as cause but as consequence of the tumorigenic status. 
Nevertheless, several microRNAs were identified as aberrantly expressed by more than 
one study, these microRNAs were most likely involved in liver tumorigenesis. Consistent 
deregulation of miR-122, miR-199, miR-221, and miR-21 appears to be particularly 
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important in HCC; among these miRNAs both miR-122 and miR-199a are among the miRs 
most highly expressed in normal liver [Hou J et al, 2011].  
miR-122 is a hepato-specific miRNA, accounting for more than 70% of the total liver 
miRNA population and it acts as a key regulator of fatty acid and cholesterol metabolism 
[Jopling C, 2012] and as a regulator of the differentiation of adult hepatocytes via 
repression of genes not specific to the liver [Xu H et al, 2010; Esau C et al, 2006; Krutzfeldt J et 
al, 2006]. The loss of its expression was observed in more than 70% of HCC and one of the 
mechanisms through which it plays an active role in tumorigenesis appears to be the 
activation of cyclin G1 [Gramantieri L et al, 2007]. miR-221 has received much attention for 
its suggested tumor-promoting activity. It is up-regulated in 70%-80% of HCC samples and 
HCC cells overexpressing miR-221 show increased growth, proliferation, migration, and 
invasion capability [Garofalo M et al, 2009; Pineau P et al, 2010]. miR-21 has been shown to 
be overexpressed in HCC as well as in other several human malignancies, including breast, 
colon, lung, pancreas, prostate, and stomach cancer [Volinia S et al, 2006]. Discovery of 
aberrantly expressed miRNAs in HCC has helped to reveal novel mechanisms of liver 
tumorigenesis. Furthermore, since the profiling of miRNA expression levels in HCC could 
be associated with bio-pathological and clinical features, miRNA expression can be a 
potential useful tool for HCC classification and for improving prognostic stratification, in 
particular in early HCC, where the availability of potentially curative treatments requires a 
more sophisticated diagnostic approach. 
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2. SOLT-FARBER MODEL OF LIVER CARCINOGENESIS 
 
Cumulative clinical and experimental evidence over several decades suggests that 
carcinogenesis is a multistage process which may involve a series of sequential cellular 
alterations. In tissues, evidence of this ongoing process may present as new cell 
populations with altered organizational, structural, and biochemical properties. 
Unfortunately, knowledge about molecular events in early stage HCC development is 
limited because of clinical difficulties in the histopathologic distinction between non-
malignant nodular lesions (low grade and high grade dysplastic nodules) from early HCC. 
Animal models facilitate the study of different stages of hepatocarcinogenesis in that 
discrete lesions at different stage of progression can be identified and analyzed, thus 
helping to detect molecular alterations already present at early pre-neoplastic stages.    
The sequential analysis of the early steps in carcinogenesis in liver is based on a principle 
formulated as early as 1938 by Alexander Haddow, who observed that cancer cells can 
arise under conditions (e.g., carcinogen exposure) which inhibit the growth or otherwise 
impair the life of normal cells (Fould L, 1954; Fould L, 1964 ). This phenomenon of "selective 
cytotoxicity" also appears to result in preferential growth of carcinogen altered cells 
which have not yet acquired all the attributes of malignancy (Farber E, 1973).                   
One of the most widely used experimental models for the characterization of the 
hepatocarcinogenesis process is the Resistant-Hepatocyte Model, also known as Solt-
Farber Model, which allows to carry out the analysis of the different sequential steps 
leading to HCC development, using the rat as animal model (Solt DB et al, 1977). In this 
model, initiation is achieved through a single necrogenic administration of a chemical 
carcinogen, diethylnitrosamine (DENA), followed by a promoting regimen consisting of a 2 
weeks-diet supplemented with the selective inhibitor of hepatocyte proliferation,            
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2-acetylaminofluorene (2-AAF), coupled with a powerful growth stimulus, such as 67% 
partial hepatectomy (PH). This protocol allows expansion of DENA-initiated cells that 
rapidly proliferate to develop into nodules (Sold D and Farber E, 1977), identified by their 
immunohistochemical positivity for the placental form of the enzyme glutathione-S-
transferase (GST-P). The subsequent fate of the nodules is variable. In the following 
weeks, nodules become macroscopically visible and occupy most part of the liver.       
Later on, a significant number of pre-neoplastic lesions undergoes a process of 
maturation and remodeling, merges with the surrounding original liver, gradually loses 
the staining for GST-P, and reacquires a differentiated phenotype (Enomoto K et al, 1982). 
Conversely, a minority of nodules persists, with some of them giving raise to adenomas, 
and after 10-14 months after DENA, to HCC. Recently, it was found that GST-P+ pre-
neoplastic nodules can be further divided into Cytokeratin 19 (KRT-19) positive or 
negative lesions, depending on the expression of KRT-19, an intermediate filament 
protein, normally expressed in adult liver by the bile duct epithelial cells, but not by 
normal hepatocytes (Andersen JB and al, 2010). Previous studies conducted in our 
laboratory showed that all the HCCs arising in the Solt-Farber model are KRT-19+, 
although only a minority of pre-neoplastic lesions developed at early stages of the 
process are positive for this marker. Furthermore, HCCs and KRT-19+ nodules share a 
common gene expression profile, suggesting that in the Solt-Farber model HCCs are 
derived from this sub-population of KRT-19+ pre-neoplastic lesions. The translational 
value of the Resistant Hepatocyte model has already been demonstrated with 
comparative genomic studies, and showed that the HCCs generated with the Solt-Farber 
model have a gene expression signature very similar to a specific human HCC subtype 
that express KRT-19 (characterized by worst prognosis) (Andersen JB et al, 2010).  
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More recently, studies performed on the R-H model have also shown that the expression 
signature of genes and microRNAs is quite similar between HCC and early preneoplastic 
lesions; this finding suggests that some of these genes/microRNAs alterations might 
represent critical events in HCC development (Petrelli A et al, 2014). 
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3. INTERMEDIATE FILAMENT OF CYTOSKELETON  
 
 Intermediate filaments (IFs) represent the largest cytoskeletal gene family comprising 
>70 genes expressed in tissue specific manner. Together with the actin microfilaments 
and the microtubules, intermediate filaments (IFs) are the components of the 
cytoskeleton of eukaryotic cells, that is involved in the maintenance of cell shape, 
locomotion, intracellular organization, and transport (Bershadsky and Vasiliev 1988; Ku et al. 
1999). Individual IF proteins consist of a conserved central coiled-coil α-helical rod domain 
(interrupted by linkers) which is flanked by N-terminal (head) and C-terminal (tail) 
domains. The N- and C-terminal domains contribute to the structural heterogeneity and 
are major sites of posttranslational modifications with phosphorylation being the best 
characterized one (Omary et al. 2006; Godsel et al. 2008; Kim and Coulombe 2007; Herrmann et 
al. 2007; Goldman et al. 2008). This makes them important regulatory domains, since 
dynamic changes in phosphorylation status are responsible for alterations in IF dynamics, 
solubility, and organization. In addition to the posttranslational modification, IF function 
is modified and complemented through interaction with a variety of IF-associated 
proteins (IFAP). These proteins can be subdivided into several subgroups, which reflect 
multiple IF functions. For example, IFs interact with a variety of anchoring proteins 
thereby forming transcellular networks which contribute to proper tissue architecture 
(Strnad et al, 2008). IFAPs also include several cytolinker proteins (i.e. proteins connecting 
different cytoskeletal filaments and other intracellular components), which provide the 
structural framework for coordinated cytoskeletal function (Green et al. 2005; Omary et al. 
2006).  
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 In contrast to the actin and tubulin system, IFs emerged later in the evolution and are 
important supportive elements of the cell rather than their essential components. 
Therefore, IF variants are observed in various human diseases, which reflect their tissue 
specific distribution, whereas only few actin and tubulin variants have been described so 
far, likely due to their embryolethality. More than 30 diseases are caused by/associated 
with IF mutations (see Table 1; Strnad et al, 2008). 
 
Table 1 Intermediate filament proteins, a Not a causative association, variants represent a risk 
factor. (Strnad et al, 2008).  
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3.1 INTEMEDIATE FILAMENT OF THE LIVER 
The liver consists of different cell types with characteristic IF composition. Keratins 
represent the largest subfamily of IFs consisting of >50 unique gene product members 
(Schweizer et al. 2006; Kim and Coulombe 2007; Godsel et al. 2008) which include 37 epithelial 
and 17 hair keratin members in humans (Schweizer et al. 2006). Epithelial keratins can be 
subdivided in types I (acidic) and II (basic) corresponding to keratins 9–20 (K9-K28) and 
keratins 1–8 plus keratins 71–80 (K1–K8; K71–K80), respectively (Coulombe and Omary 
2002; Schweizer et al. 2006). Keratins are found as obligatory type I and type II 
heteropolymers (i.e., consisting of at least one type I and one type II keratin) and a 
homozygous disruption of a keratin results in degradation of its keratin partner at the 
protein level (Ku and Omary 2000; Omary et al. 2004). Similarly to IFs, keratins are expressed 
in a tissue specific manner, with different pairs being the major cellular IFs in different cell 
populations (Moll et al. 1982; Ku et al. 1999; Coulombe and Omary 2002).  
Adult hepatocytes are unique among epithelial cells in that they express exclusively K-8 
and K-18, whereas other glandular epithelia exhibit a more complex keratin expression 
pattern (Omary et al. 2002; Ku et al. 2007). The hepatocytic keratin IF network is dense, 
particularly around bile canaliculi and at the cell periphery, and acts as cytoskeletal 
backbone to the functionally more dynamic and contractile actin-micro-filament system 
(Strnad et al, 2008). Biliary epithelial cells differ from hepatocytes by additional expression 
of keratin 7 and 19. Keratins in cholangiocytes, but not hepatocytes, exhibit polarized and 
compartment-specific expression pattern (Zatloukal et al. 2004). The biological significance 
of such expression and distribution is incompletely understood, but it may be related to 
cell polarity and secretory processes.  
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Among nonepithelial cells, stellate cells express variable amounts of glial fibrillary acidic 
protein (GFAP), desmin, vimentin, and nestin dependent on their activation status, 
localization, and other parameters (see Table 2; Strnad et al, 2008 modified from Omary et 
al. 2002). 
 
 
Table 2 IFs of liver cell populations (P. Strnad et al, 2008 modified from Omary et al. 2002). 
a During embryogenesis, hepatocytes also express variable levels of K19 (Vassy et al. 1997). 
b Stellate cells represent a highly heterogeneous population with variable IF expression dependent 
on species, activation status of the cell, location within the hepatic lobe and many other 
parameters. (Geerts et al, 2001). 
 
 
 
The large body of evidence from animal studies showing the importance of K-8/K-18 for 
liver homeostasis led to a search for keratin mutations in patients with liver diseases. 
Several K8/K18 variants were found to associate with the development of cryptogenic 
liver disease (Ku et al. 2001). In subsequent studies, K8/K18 were shown to represent 
susceptibility genes for the development of end-stage liver disease of multiple etiologies 
(Ku et al. 2005). Moreover, abnormal expression of K-19 in the hepatic parenchyma has 
been attributed to remodeling of cirrhotic nodules and hepatic progenitor cell (HPC) 
proliferation (Su Q et al, 2003). In previous studies it has been identified a subclass of 
human HCC that is enriched for the genes expressed in fetal hepatoblasts (Lee JS et al, 
2006), including the progenitor cell markers K-7 and K-19.  
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The K19-HCC subtype was characterized by the worst clinical prognosis among all HCC 
subclasses, suggesting that K19 is a prognostic marker for HCC (Andersen JB et al, 2010; Lee 
JS et al, 2006; Wu PC et al, 1996). 
 
 
3.2 ROLE OF NEUROFILAMENT-LIGHT POLYPEPTIDE (NEFL) IN TUMORIGENESIS 
 
Neuronal Intermediate Filaments (NF) represent a major component of the neuronal 
cytoskeleton, and are believed to function primarily to regulate axon diameter and play a 
key role in maintaining the morphology of neurons and in regenerating myelinated axons. 
NF are composed of polypeptide chains which belong to the same protein family as the 
intermediate filaments of other tissues such as keratin subunits. NF consist of three 
subunits: a light (NEF-L), a medium (NEF-M) and a heavy polypeptide (NEF-H), with 
molecular weights of 68 kDa, 160 kDa and 212 kDa respectively (Liem RK et al, 1978). The 
NEFL gene encodes type IV intermediate filament heteropolymers that functionally 
maintain the neuronal caliber and play an important role in the intracellular transport of 
neurotransmitters to axons and dendrites. The targeted disruption of the NEFL gene in 
mice confirmed the importance of NF-L in IF assembly [Zhu Q, et al, 1997]. In absence of 
NF-L, the NF-M and NF-H subunits are not able to assemble into 10 nm filaments. As a 
result, mice lacking NF-L have a scarcity of IF structures and exhibit severe axonal 
hypotrophy. While the targeted disruption of the NEFL gene in mice provided definite 
proof that neurofilaments are a major determinant of axonal caliber, the specific roles of 
NF-M and NF-H subunits remain unclear [Julien JP, 1999; Zhu Q, et al, 1997].  NF 
accumulations have been described in several neurological diseases where abnormal IF 
accumulations can provoke a gradual block of axonal transport.  
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Various factors may lead to the formation of abnormal IF aggregations, including 
deregulation of IF gene expression, neurofilament mutations, and post-translational 
modifications (such as phosphorylation, glycosylation, nitration and protein crosslinking). 
Notably, NEFL mutations have been associated with Charcot-Marie-Tooth disease type 2E 
(CMT2E), Parkinson’s disease and amyotrophic lateral sclerosis (Mersiyanova IV et al, 2000). 
In addition to the important structural role of intermediate filaments, other cellular 
functions are being increasingly ascribed to IF. Indeed, it has been recently demonstrated 
a physiological role of NEFL in regulating mitochondrial morphology, fusion, and motility 
in neurons; interestingly, disruption such functions occurs in Charcot-Marie-Tooth (CMT) 
disease type 1F, due to point mutations in the NEF-L gene (De Jonghe et al., 2001; Jordanova 
et al., 2003).  
Although studies regarding the role of the NEFL protein have been mostly focused to 
neurological diseases, such as Charcot–Marie–Tooth’s disease (CMT), recent evidence 
points to a correlation between NEFL expression and cancer development. Indeed, a 
growing number of studies suggest that NEFL may act as a tumor suppressor in various 
tumors including breast cancer (Li XQ et al., 2012) and head and neck cancer (Chen B et al., 
2012). The NEFL gene is located on human chromosome 8p21, a region enriched with 
tumor suppressor genes. Loss of heterozygosity (LOH) is frequent in this region (Imbert A. 
et al, 1996, Kochanski A, 2004) and is involved in breast (Li XQ et al, 2012; Kerangueven F et al, 
1995; Seitz S et al, 2000; Yaremko ML et al, 1996), prostate (Macoska JA et al, 1995; Haggman 
MJ et al, 1997; Kagan J et al, 1995; Schmidt H et al, 2007; Vocke CD et al, 1996), lung (Kurimoto F 
et al, 2001; Lerebours F et al, 1999), colon (Lerebours F et al, 1999; Takanishi DM et al, 1997), 
and urinary bladder cancers (Knowles MA, 1993). 
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LOH at the NEFL locus is a common genetic alteration in infiltrating and in situ breast 
cancer (Anbazhagan et al. 1998). Notably, in breast cancer, LOH at the NEFL locus is 
associated with the presence of stromal invasion by tumor cells and therefore correlates 
with invasive capacity (Yaremko ML et al, 1996). Interestingly, although NEFL in normal 
tissues is expressed in neurons with strict histological specificity, it was recently 
demonstrated that ectopic NEF-L mRNA expression can be detected in various 
malignancies including breast cancer (Li XQ et al., 2012). Notably, in breast cancer NEFL is 
down-regulated in lymph node metastases compared to the primary tumors (Li XQ et al, 
2012). Moreover, a low NEFL mRNA expression level was found to be a prognostic factor 
to predict disease-free survival of early-stage breast cancer patients (Li XQ et al, 2012). 
These data indicate that the ectopic occurrence and change in NEFL mRNA expression 
levels play an important role in tumor development and metastatic process in breast 
cancer, although the exact role of NEFL expression in cancer and its prognostic power for 
breast cancer patients remains unclear.  
In head and neck cancer (HNC), LOH at the NEFL locus has been shown to decrease 
survival time in patients with advanced tumor stage (Coon et al., 2004). Furthermore, in 
head and neck cancer cell lines, NEFL mRNA expression has been shown to positively 
correlate with cancer cell apoptosis, and negatively correlate with cancer cell growth and 
invasion capacity (Huang Z, 2014). Another study showed that, in head and neck cancer 
cell lines, downregulation of NEFL mRNA was due to hypermethylation of the NEFL gene 
promoter and correlated with increased resistance to cisplatin (Chen B et al. 2012). 
Furthermore, in patients treated with cisplatin-based chemotherapy, hypermethylation of 
the NEFL gene correlated with resistance to the therapy and diminished overall and 
disease-free survival (Chen et al. 2012). Several studies examined potential pathways 
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modulated by NEFL. As described in the literature, NEFL interacts with multiple protein 
targets essential for cell plasticity, proliferation, migration, apoptosis, molecule transport 
(Haddad LA. Et al, 2002) and functional molecular targets of NEFL are found in several 
critical cancer-associated pathways. Among these, some authors investigated the 
Tuberous Sclerosis 1 (TSC1) tumor suppressor. TSC1 has been shown to function as a 
molecular inhibitor of the mTOR oncogenic pathway, reported to be frequently 
constitutively activated in cisplatin-resistant cancers cell lines (Mabuchi S. et al, 2009). NEFL 
has been shown to bind TSC1 and stabilize the TSC1/2 complex (Haddad LA . et al, 2002). 
Therefore, it was hypothesized that inactivation of NEFL, leading to abnormal activation 
of the mTOR pathway, confers cisplatin-resistance in head and neck cancer. mTOR is a key 
downstream protein kinase of the phosphatidylinositol 3-kinase (PI3K)/AKT signaling 
pathway and has been reported to play a central role in controlling cancer cell growth 
(Zoncu R. et al, 2011). AKT and mTOR function as "switch" proteins to modulate 
metabolism, the cell cycle, and apoptosis in cancer cells (Foster DA. Et al, 2009; Castedo M. 
et al, 2002). Constitutive activation of mTOR is common in human malignancies. In 
cultured cortical neurons, NEFL was found to physically bind to the putative tumor 
suppressor TSC1 (Haddad LA. Et al, 2002), a molecular inhibitor of mTOR activity. NEFL has 
also been shown to physically interact with glutamate receptor, ionotropic, NMDAR1, a 
subunit of NMDAR, that has recently been shown to be a novel tumor suppressor gene in 
esophageal carcinoma (Kim MS, et al, 2006). 
Julien et all [Julien JP, 1999] speculated that neurofilaments might have a protective role 
against the toxic effects induced by SOD1 mutations. Based on this hypothesize, they 
speculated that the change in NEFL mRNA expression level is involved in the process of 
adaptive cytoprotection.  
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When malignant transformation takes place in the presence of physical/chemical 
carcinogen, tissue cells change their expression profile to adapt to the new 
microenvironment and to retain the function of normal tissue cells as much as possible 
[Kim MS, et al, 2006].  
Despite evidence linking the NEFL gene to the development of head-and-neck and breast 
cancer, very little is known on the potential involvement of the NEFL gene in other 
tumors, such as HCC. Indeed, the only evidence linking the NEFL gene with HCC 
development is provided by genetic studies that report the frequent LOH of the NEFL 
locus region in human hepatocellular carcinoma (Becker et al., 1996). However, whether 
and which role NEFL may play in HCC development remains totally unknown.   
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AIM OF THE WORK 
It is now becoming increasingly evident that molecular pathogenesis of HCC cannot be 
understood without a more detailed knowledge of the molecular alterations 
characterizing its early development. Therefore, one of the priorities in this field of 
investigation is the identification of key molecular players that drive the 
hepatocarcinogenesis process starting from its early stages. In this respect the Resistant 
Hepatocyte (R-H) model of rat carcinogenesis it a valuable one, since i)it allows the 
analysis of the hepatocarcinogenesis process starting from the very early preneoplastic 
stages and ii)it has been proven to be of translational value for the human pathology. 
As mentioned, very little is known on the involvement of the NEFL gene in the process of 
hepatocarcinogenesis; therefore whether NEFL plays a role in HCC development is still 
largely unknown.  
Thus, the goal of the present study was to investigate the role of NEFL in the onset and 
progression of HCC in the R-H rat model of hepatocarcinogenesis, and human HCCs. 
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MATERIALS AND METHODS 
Animals  
Male  Fisher F-344 rats ( Charles River, Milan, Italy) weithing 100-125 gr have been used 
for this studies. Animals have been fed a standard diet (Mucedola, Milan, Italy) and 
maintained  at 25 °C temperature  and 12 hours light/dark dayily cycle, with food and 
water ad libitum. Guidelines for the Care and Use of Laboratory Animals were followed 
during the investigation. All animal procedures were approved by Ethical Commission of 
the University of Cagliari and the Italian Ministry of Health.  
Experimental Protocol 
Rats belonging to the experimental group were treated in accordance with the Resistant 
Hepatocyte Protocol (R-H model). Animals were injected intraperitoneally (i.p.) with a 
single dose of diethylnitrosamine (DENA)  (Sigma Aldrich, St. Louis, MO,USA), dissolved in 
saline, at a dose of 150 mg/kg body weight. After a 2-week recovery period, rats were fed 
a diet containing 0.02% 2-acetylaminofluorene (2-AAF) (Sigma Aldrich, St. Louis, MO,USA) 
for 1 week, followed to a standard two-thirds partial hepatectomy (PH) (Higgins GM and 
Anderson RM, 1931), and kept for an additional week on the 2-AAF-containing diet. The 
animals were then switched to basal diet all throughout the experiment. Two additional 
groups were used as controls: one group was subjected to the promoting regime            
(2-AAF+PH) in the absence of carcinogen, and in a second group both the initiating and 
the promoting regimes have been omitted. Each experimental group was divided into two 
subgroups; the first of them was sacrificed at ten weeks from DENA administration, at a 
time when GSTP-positive pre-neoplastic lesions are present; the second one has been 
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sacrificed at fourteen months to evaluate the presence of fully developed HCCs.          
HCCs were selected on the basis of the criteria proposed in “histologic typing of livel 
tumors of the rats” (Stewart HLW,1980).  
 
For assessment of NEFL expression during liver regeneration, rats were subjected to a 
standard 2/3 Ph according to the method described by Higgins and Anderson (Higgins GM 
and Anderson RM, 1931), and sacrificed after 24 hours after PH. Livers collected at the 
time of surgery were used as controls. 
Treatment with 5’-bromo-deoxyuridine (BrdU) 
In order to assess the proliferative activity of hepatocytes, rats subjected to the analysis 
of KRT-19- and KRT-19+ preneoplastic lesions and animals subjected to PH were treated 
with 5’-bromo-deoxyuridine (BrdU) (Sigma Chemical Co., St Louis, MO, USA). For 
assessment of proliferative activity in pre-neoplastic lesions, BrdU was dissolved in 
drinking water (1mg/mL) and given ad libitum for 7 days before sacrifice. For assessment 
of hepatocyte proliferation during liver regeneration associated to PH, BrdU was 
administered intra-peritoneally (i.p.) 2 hours prior to sacrifice at a dose of 50 mg) 100gr 
body weight. 
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Histology, Immunoistochemistry, Immunofluorescence and Western blot analyses 
 
Tissue preparation 
Immediately after sacrifice, livers were cut into several pieces and subjected to different 
analyses. For immunoistochemitry analysis, liver sections were fixed in 10% formalin, 
embedded in paraffin and stored at RT. Other sections were frozen in cold isopentane or 
quickly frozen by immersion in liquid nitrogen and stored at -80 °C.  
Hematoxylin and Eosin staining 
Four micrometer-thick (4 um) paraffin-embedded livers sections were deparaffinized in 
xylene and then hydrated in a decreasing series of alcohol. Sections were then stained 
with Carazzi Hematoxylin for 15 min and in 1% acidified alcoholic eosin for 30 seconds, 
then dehydrated in ascending series of alcohol.  
GST-P and KRT-19 Immunoistochemistry 
Six micrometer-thick (6 um) isopentane-frozen liver sections were fixed in acetone at -20 
°C for 20 minutes. Endogenous peroxidases were blocked with Peroxidase Block Reagent 
(Dako, Milan, Italy) for 10 minutes. Blocking of aspecific sites was performed in normal 
goat serum 1:10 in PBS buffer for 1 hour at RT. Anti-GSTP antibody (rabbit polyclonal 
antibody MBL, Germany) was applied overnight at 4 °C at 1:1000 diluition. Sections were 
then incubated with anti-rabbit HRP secondary antibody at 1:200 diluition for 1 hour at 
RT. Sections were then stained by a brief incubation with 3-3’ diaminobenzidine 
tetrahydrochloride hydrate (DAB) (Dako Envision, Denmark). KRT-19 protein was detected 
by applying anti-KRT-19 primary antibody (mouse monoclonal antibody Novacastra, Leica 
Biosystem, Milan) diluted 1:50 for 2 hours at RT and by incubation sections with anti-
mouse HRP secondary antibody 1:200 in PBS at RT for 1 hour. Staining was revealed by a 
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solution containing the chromogenic DAB. Counter staining was performed with Harris 
Hematoxylin Solution (Sigma-Aldrich, St Louis, MO, USA). Finally, sections were 
dehydrated in ascending series of alcohol and mounted with coverslip.  
Immunofluorescence 
Six micrometer-thick (6 um) isopentane-frozen liver sections were fixed with methanol for 
10 min. Allow sections to fix for 10 min at room temperature. Rinse slides three times in 
PBS-T for 5 min each. Block specimen in blocking buffer (1X PBS/ normal goat serum) for 
40 min. tissue were then stained overnight at 4°C  with the following primary antibody 
diluited in PBS: anti-NEFL antibody (rabbit monoclonal antibody, Cell Signaling), anti-KRT-
19 primary antibody (mouse monoclonal antibody Novacastra, Leica Biosystem, Milan), 
Anti-GSTP antibody (rabbit polyclonal antibody MBL, Germany). Sections were  washed 
with PBS and incubate for 2 h with the respective secondary antibody conjugated to Alexa 
FluorR 594 goat anti–mouse IgG (H+L), Alexa FluorR 488 goat anti–rabbit IgG (H+L)(Life 
Technologies). Slides were then rinsed in PBS and coverslip slides with DAPI (4-6-
DIAMIDINO-2-PHENYLIN, Life Technologies).  
Protein isolation 
Rat liver samples were homogenized in RIPA Buffer (10 mM Tris-HCL pH 8.0, 1 mM EDTA, 
1% Triton X-100, 0.1% sodium deoxxycholate, 0.1% SDS, 140 mM NaCl) containing 
protease and phosphatase inhibitors (Sigma-Aldrich, St Louis, MO, USA), incubated for 2 h 
at 4 °C with shaking and centrifuged at 1200 rpm for 20 min at 4 °C. the supernatant was 
collected and stored at -80 °C. protein concentration of whole-cell lysates was evaluated 
with BCA Protein Assay kit (Pierce Biotecnology, Rockford, USA) and equal amount of 
total protein were used to perform western blotting experiments.  
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Western blotting 
100 ug of protein were resolved in NuPAGE Tris-Acetate Mini Gel 7% (Life Technologies, 
Carlsbad, USA) and transferred to nitrocellulose membrane. The membranes were 
blocked for 1 h at RT in 5% Bovine Serum Albumin (BSA) (Sigma-Aldrich, St Louis, MO, 
USA) diluted in TBS-T buffer (NaCl 5M, Tris-HCl 1M pH 7.4, 0.1% Tween-20), washed three 
times in TBS-T for 10 min, and incubated overnight at 4 °C with anti-NEFL antibody (rabbit 
monoclonal antibody, Cell Signaling) 1:500 in 5% BSA. After washing 3 times for 10 min in 
PBS, membranes were incubated for 1h at RT with anti-rabbit peroxidase-conjugated IgG 
secondary antibody at 1:1000 dilution (Santa Cruz Biotecnology, CA, USA) and the washed 
3 times for 10 min in PBS. Protein were detected using Supersignal West Pico 
Chemiluminescent Substrate (Pierce Biotecnoly, Rockford, IL, USA). Subsequently, 
membranes were stripped and incubated 1 h with anti-β-actin antibody diluted 1:500 
(Monoclonal anti-Actin, Clone AC-40, Sigma-Aldrich, ST. Louis, MO, USA), washed 3 times 
with PBS and incubated for 1 h at RT with HRP-conjugated anti-mouse secondary 
antibody at 1:1500 dilution, washed 3 times and then subjected to the final detection 
step. Levels of NEFL proteins were normalized to expression of the housekeeping gene β-
actin was used as loading control.  
 
Laser-capture Micro-dissection (LMD) 
Pre-neoplastic lesions of animals sacrificed ten weeks after initiation were identified by 
immunoistochemical staining for GST-P and KRT-19 proteins. Fourteen-um-thick serial 
frozen sections were attached to 2-um PEN-membrane slides (Leica, Bannockburn, IL). 
Immediately before performing dissection, each section was rapidly stained with a 2.45 
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minutes H&E staining. This step was performed in order to identified the localization of 
the lesions of our interest, which were previously identified  on serial sections subjected 
to GST-P and KRT-19 IHC. Micro-dissection was performed using a Leica laser 
microdissection apparatus (Leica, LMD6000). RNA was extracted from micro-dissected 
samples using the PicoPure RNA Isolation kit and mirVana miRNA Isolation kit (mirVana) 
according to manufacturer’s instructions.  
 
RNA EXTRACTION 
RNA extraction from pre-neoplastic lesions: total RNA was extracted from preneoplastic 
lesions and from respective control livers with mirVana miRNA Isolation kit  (mirVana, 
Ambion, Life Tecnologies, Monza) according to manufacturer’s instructions. Briefly, 
dissected lesions were dissolved in 300 µl of Lysis Buffer (LB) and 30 µl of miRNA 
Homogenate Additive. After 10 min incubation on ice, 300 µl of acid-phenol:chloroform: 
isoamyl alcohol (125:24:1) were added to samples. Samples were then centrifugated for 5 
min at maximum speed to separate the aqueous and organic phases. After recovery of 
the aqueous phase, 1.25 volumes of 100% ethanol were added and the mixture was 
transferred to a filter cartridge. Samples were centrifuged and, after three washing steps 
with Wash Buffer, RNA was eluted in 100 µl of DEPC pre-heated water (95 °C).  
RNA purification from rat HCCs and control livers: total RNA from advanced HCCs (14 
months after DENA) and control livers was isolated using TrizolR Reagent (Invitrogen, 
Carlsbad, CA, USA).  1 ml of Trizol was added to 80-100 mg of hepatic tissue and samples 
were homogenized with a power homogenizer. After a centrifugation step of 10 min at 
12000 g at 4 °C, samples were incubated 5 min at RT to permit the complete dissociation 
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of nucleoprotein complex. 0.2 ml chloroform for each ml Trizol used were added and 
samples were centrifuged 15 min at 12000 x g. After centrifugation the mixture separates 
into a lower red phenol-chloroform phase containing proteins, a white interphase 
containing DNA, and a colorless uppers aqueous phase containing RNA. RNA was then 
precipitated by addition of 500 µl isopropanol (Fisher Scientific, Thermo Fisher Scientific, 
France) and subsequently with 1 ml of 100% ethanol. Finally, the pellet RNA was dissolved 
in RNase-free water (Gibco, Life Technologies, Milan). In order to completely eliminate 
proteoglycans and polysaccharides (glycogen), the eluted RNA was subjected to a further 
purification process conducted using 3M sodium acetate pH 5.2. After a second 
precipitation in 75% ethanol, the RNA pellet was air dried and then resuspended in 
RNase-free water.  
Quantitative and qualitative analysis of nucleic acids    
RNA concentration was determined with a Nanodrop spectrophotometer (Thermo 
Scientific, France) and its quality was assessed with an Agilent 2100 Bioanalyzer (Agilent 
Technologies, Milano, Italy). Only RNA samples with a RIN (RNA Integrity Number) equal 
to seven or higher were included in the study. 
 
Microarray                                                                                                                                                                        
Liver RNA was extracted and purified from each individual lesion laser microdissected 
samples  (10 control liver samples, 10 pre-neoplastic KRT-19- microdissected lesions, 10 
pre-neoplastic KRT-19+ microdissected lesions, 4 microdissected Adenomas, 5 
microdissected early HCC and 9 fully malignant HCC, all samples were obtained from       
F-344 rat subjected to R-H model). 150 ng of RNA were amplified (Illumina TotalPrep RNA 
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Amplification Kit), labeled and hybridized on Illuminamicroarray (BeadChips, Illumina Inc., 
San Diego, CA, USA) including 21.791 gene specific oligonucleotide probe.  
The Illumina® TotalPrepTM RNA Amplification Kit is a complete system for generating 
biotinylated, amplified RNA for hybridization with Illumina Sentrix® arrays. The procedure 
consists of reverse transcription with an oligo(dT) primer bearing a T7 promoter using 
ArrayScript™, a reverse transcriptase (RT) engineered to produce higher yields of first 
strand cDNA than wild-type enzymes. ArrayScript catalyzes the synthesis of virtually full-
length cDNA, which is the best way to ensure production of reproducible microarray 
samples. The cDNA then undergoes second strand synthesis and cleanup to become a 
template for in vitro transcription with T7 RNA Polymerase. To maximize cRNA yield, 
Ambion® MEGAscript® in vitro transcription (IVT) technology along with biotin-UTP 
(provided in the kit) is used to generate hundreds to thousands of biotinylated, antisense 
RNA copies of each mRNA in a sample. (In this protocol the antisense amplified RNA is 
referred to as cRNA, in scientific literature it is also commonly called aRNA.) The labeled 
cRNA was hybridized with Illumina arrays (RatRef-12 V1 BeadChips).  
Microarray data analysis 
The intensity files were loaded into the Illumina BeadStudio 3.0.19.0 software (Illumina 
Inc) and BRB Array Tools (Version 4.2.0) for quality control and gene expression analysis. 
First, the quantile normalization algorithm was applied on the dataset. Only genes whose 
expression differed by at least 1.5 fold from the median in at least 20% of the arrays and 
characterized by a 50th percentile of intensities greater than 300 were retained. The FDR-
adjusted p-values were calculated using the Benjamini-Hochberg procedure (Benjamini Y 
and Hochberg Y, 1995). According to these criteria, 1.144 expressed transcripts out of 
21.791, showed reproducible up- or downregulation. Custom R scripts based on the 
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Limma package (Smyth GK, 2005) were used to identify genes differentially expressed at    
p ≤ 0.01 between early nodules and advanced lesions, based on Log2ratio expression data 
(median centered). Normal livers were used as reference. Following this analysis, 869 
genes showed reproducible up- or down-regulation in at least one comparison. Log2ratio 
expression data were clustered and visualized in the heat-maps using the GEDAS software 
(Fu L and Medico E, 2007) using Pearson correlation as distance matrix and Complete 
Linkage as method of calculating distance between clusters. 
Functional analysis by means of the Ingenuity IPA Software: rat standard gene symbols 
(RGD ids) were submitted to the Ingenuity IPA analysis pipeline and converted to human 
gene id, were possible. Analysis of the pathways was based on the number of genes 
significantly dysregulated (fold difference cutoff ±2.0) with corresponding biological 
functions, with the restriction of at least 8 genes per function to emphasize the functions 
with most genes differentially expressed. The significance of each network and the 
connectivity was estimated in IPA. 
 
Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
To perform the analysis of mRNA and microRNA expression, the RNA has been 
retrotrascribed to cDNA using two different protocols:        
– High Capacity cDNA Reverse Transcription Kit (Applied Biosistem, Life Technologies, 
Monza, Italy) used for mRNA analysis. 1.5 µg of RNA were diluted in 10 µl of RNase free 
water to a final concentration of 150 ng/µl. For each sample 2 µl of RT Buffer (10X), 2 µl of 
Random Primers (10X), 0.8 µl of dNTPs (100 mM), 1 µl of MultiScribe Reverse 
Transcriptase enzyme, 1 µl of RNase Inhibitor and water until 20 µl were added.  
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Sample were then incubated at 25 °C for 10 min, at 37 °C for 120 min and 85°C for 5 
minutes. Sample were then stored at -20°C until use.    
-TaqManR MicroRNA Reverse Transcription Kit (Applied Biosistem, Life Technologies, 
Monza, Italy) was used for the retrotranscription of microRNAs. 10 ng of total RNA were 
diluted to reach a final concentration of 2 ng/µl. For each sample, the retro-transcription 
mixture was composed of: 4.16 µl of dH2O, 1.5 µl of Reverse Transcription Buffer (10X), 
0.12 µl of dNTPs (100 mM), 0.19 µl of RNase Inhibitor and 1 µl of MultiScribe Reverse 
Transcriptase. For each miRNA 3 µl of specific primer were used. Subsequently the 
samples were incubated at 16 °C for 30 min, then at 42 °C for 30 min and at 85 °C for 5 
min. samples were then stored at -20 °C until use. 
qReal Time PCR 
Retro–transcribed cDNAs were used for the assessment of mRNA and microRNA 
expression levels by real-time PCR. For gene expression analysis, the amplification 
reaction was performed in a final volume of 10 µl containing: 4 µl of cDNA (2.5 ng/µl), 5 µl 
of TaqMan Gene Expression Master Mix (Applied Biosistem, Life Technologies, Monza, 
Italy) and 1 µl of TaqMan probe (Applied Biosistem, Life Technologies, California, USA). 
The following TaqMan probes were used: -Rn00582365_m1 for the analysis of rat NEFL;   
-Hs01034882_m1 for the analysis of human NEFL.  
For the analysis of microRNAs expression, the RT product was diluted in 52 µl of dH2O.  
4.5 µl of the diluted cDNA was amplified with 14.5 µl of TaqMan Universal Master Mix II 
no UNG (Applied Biosistem, Life Technologies, Monza, Italy) and 1 µl of a specific TaqMan 
microRNA Assays (Applied Biosistem, Life Technologies, California, USA). The following 
TaqMan miRNA probes were used: -002223 for the analysis of miR-30e; -000420 for the 
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analysis of miR-30d. Parameters  used to perform the reaction are: 10 min at 95 °C 
followed by 40 cycles at 95 °C for 15 sec each and a final step at 60 °C for 1 min. for both 
mRNA and miRNAs expression, each sample was analyzed in triplicate. The housekeeping 
gene β-action or GAPDH for gene expression and 4.5S (rat) or U6 snRNA (rat-mouse) and 
RNU48 (human) for miRNAs expression were used for normalization. Expression levels 
were evaluated with the 2-∆∆Ct method and represented as relative expression compared 
to a calibrator control.  
  
Methylation analysis and sequencing 
Genomic DNA was extracted from normal liver and HCC tissues isolated from rats 
subjected to the Resistant-Hepatocyte model with QIAmp DNA mini kit (Qiagen, Valencia, 
CA) following manufacturer’s recommendations. Bisulfite conversion was performed 
using EpiTect Plus DNA Bisulfite Kit (Qiagen). 40 ng of bisulfate-converted DNA was PCR 
amplified using forward primer 5’-TTGGAGTAAGTAGAATAAGGTTTTG-3’ and biotinylated 
reverse primer 5’-AAAATCTCCTCCAACCCC-3’ (10 pmol/each) and a PCR mix containing 1.5 
mM MgCl2, O.2 mM dNTPs and 1U of Platinum Taq DNA Polimerase (Invitrogen, Carlsbad, 
CA). PCR was carried out for a total of 45 cycles (94°C for 30 seconds, 55 °C for 30 seconds 
and 72°C for 45 seconds) in a PCR system 9700 (Applied Biosystem, Foster City, CA). 
Pyrosequencing was performed according to the manufacturer’s instructions using the 
following sequencing primer: 5’GTTTTGTATGAGTAGGAG3’.  
This analysis allowed evaluation of 10 consecutive CpGs in the sequence:  
GATCTGCGACTGGCGGCCGAAGACGCCACTAACGAGAAGCAGGCGCTGCAGGGCGAGCGCG. 
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Patients  
HCC and cirrothic tissues were obtained from 14 consecutive patients undergoing liver 
resection for HCC. All tissues were obtained by Policlinico S.Orsola-Malpighi, Bologna, 
Italy (Dr. L. Gramanieri). Tissues were collected at surgery after obtaining an informed 
consent, immediately frozen in liquid nitrogen and stored at -80 °C until RNA extraction. 
Histopathological grading was scored according to Edmondson and Steiner criteria (Rozen 
S. and H.J. Skaletsky, 2000). No patient received anticancer treatment prior to surgery. 
The characteristics of patients are detailed in TableI.   
Statistical analysis 
Time to recurrence (TTR) curves based on NEFL mRNA expression level were computed by 
Kaplan-Meier product-limit method and compared using a long-rank test. Reported p-
values are two-sided and were considered significant when lower than 0.05. statistical 
calculations were performed using SPSS version 15.0 (SPSS Inc, Chicago, IL).  
 
Statistics                                                                                                                                                                          
Data are expressed as mean ± standard deviation (SD). Analysis of significance was done 
by t Student’s test and by One-Way ANOVA using GraphPad software (La Jolla, California).   
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RESULTS 
 
 
NEFL mRNA levels are up-regulated at all stages of rat hepatocarcinogenesis  
To address the putative role of NEFL in the development of HCC, we assessed the 
expression levels of NEFL in the Resistant-Hepatocyte Model, which allows the analysis of 
the different sequential steps leading to HCC development using the rat as animal model. 
A microarray transcriptome analysis performed in our laboratory (Fig.1A) revealed that 
NEFL was one of the 213 genes whose expression levels was dysregulated throughout the 
carcinogenic process, from the early pre-neoplastic stage to advanced HCCs (Petrelli A et al, 
2014). NEFL, a gene whose expression is not detectable in control rat liver, was 
overexpressed all throughout the carcinogenic process (Fig.1B), with much higher mRNA 
levels in KRT-19 positive pre-neoplastic lesions compared to KRT-19 negative ones (fold 
change over control 18.87 vs 1.29). Interestingly, NEFL mRNA expression levels declined 
at later stages of hepatocarcinogenesis, showing a trend towards control values in fully 
malignant HCC (fold change over control 17.19 in early HCCs, 1.68 in advanced HCCs).  
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Fig.1 A) Transcriptomic analysis of different hepatocarcinogenesis stages in rats subjected to the R-
H protocol. The image represents the hierarchical group of 1144 genes analyzed in control livers, 
in KRT-19- and KRT-19+, pre-neoplastic lesions in adenomas, early HCCs and in advanced HCCs. 
Each line represents the expression profile of an mRNA, and each column represents a sample. 
The red and green colors respectively indicate a high and a low expression of the examined gene. 
B) Venn diagrams show the number of differentially expressed genes in each phase of the 
carcinogenic process compared to controls. NEFL was strongly expressed in KRT-19+ pre-
neoplastic lesions, while its expression decreased towards control values in fully malignant HCC. 
Expression values for NEFL are reported as fold change over healthy liver control. (From Petrelli A 
et al, 2014). 
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To validate the cDNA microarray results, we performed qRT-PCR analysis of NEFL, and in 
agreement with transcriptome data, we observed that while NEFL mRNA was 
undetectable in normal liver (cycle threshold (CT)> 39), it was overexpressed at all stages 
of the carcinogenic process, including the pre-neoplastic ones (Fig.2 A,B). in this study, we 
analyze 20 early pre-neoplastic lesions (10 KRT-19- lesions and 10 KRT-19+ lesions), 5 
early HCC (eHCC), 9 advanced HCC (aHCC) and 10 control samples. As shown in fig.2B, 
analysis of significance by One-Way ANOVA showed a highly significant difference 
between pre-and neoplastic samples vs. control liver (p<0.0001).  
 
 
Fig.2 A) Validation of cDNA microarray NEFL gene expression data by qRT-PCR. B) qRT-PCR gene 
expression values from (A) are plotted in semi-log scale. The mRNA expression was assessed in 
control liver (n=10), KRT-19- (n=10), KRT-19+ (n=10), early HCC (n=5) and advanced HCC (n=9) 
samples. Rat β-actin was used as endogenous control. Data are expressed as mean ± standard 
deviation (SD) (mean log expression for NEFL in KRT-19- vs KRT-19+ vs eHCC vs aHCC: 3.24±0.40 vs 
4.50±0.04 vs 3.84±0.31 vs 3.36±0.43). Gene expression values are reported as fold change over 
control liver. (*** p< 0.0001 CONTROL vs KRT-19-, KRT-19+, eHCC, aHCC; * p< 0.01 KRT-19- vs 
KRT-19+; * p< 0.01 KRT-19+ vs aHCC).  
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NEFL protein is expressed in KRT-19+ preneoplastic lesions and in early HCCs  
Next, we wished to determine whether the increased NEFL mRNA levels observed in pre- 
and neoplastic stages of hepatocarcinogenesis could also result in increased protein 
content. To this aim, immunofluorescence was used to detect the presence of NEFL in 
pre- and neoplastic lesions developed 10 weeks and 10 months after initiation. Lesions 
were identified by their immunofluorescence positivity for the placental form of 
Glutathione-S-transferase (GST-P). As shown in Fig.3, while GSTP was undetectable in 
normal liver (Fig.3A), pre- and neoplastic lesions exhibited an intense fluorescent staining 
(Fig.3B-D).  
 
Fig. 3 Immunofluorescence analysis for GST-P in frozen sections of normal liver (A), pre-neoplastic 
lesions (B,C) and advanced HCC (D). Original magnification 20X. Green staining indicates GST-P 
expression, whereas blue color corresponds to nuclear staining by DAPI.  
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When we stained liver sections for NEFL, we found that consistent with mRNA expression 
data, NEFL protein expression was undetectable in control liver (Fig.4A). On the other 
hand, an intense NEFL staining was observed in HCCs developed 10 months after initiation  
(Fig.4 B-D).  
 
Fig. 4 Immunofluorescence analysis for NEFL protein expression in frozen sections of normal liver 
and early HCCs (A,C,D original magnification 20x, (B original magnification 10x). NEFL protein 
expression is indicated in green color; blue color indicates DAPI nuclear staining. 
Our previous studies have shown that the vast majority of HCCs arising in the R-H model 
of hepatocarcinogenesis are KRT-19 positive, despite the fact that KRT-19+ nodules 
represent a minority of the preneoplastic lesions developed at early stages of the process 
[Andersen JB et al 2010]. This suggests that the subset of KRT-19+ lesions has an intrinsic 
advantage in the progression to malignancy. Therefore, it is critical to understand 
whether up-regulation of NEFL occurs in all preneoplastic populations or it discriminates 
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between KRT-19+ or KRT-19- subpopulations. To this aim, we analyzed NEFL protein 
expression by immunofluorescence in the preneoplastic KRT-19+ and KRT-19-nodule 
populations. As shown in Fig.5A, NEFL protein expression was clearly observed by 
immunofluorescence in KRT-19+ preneoplastic lesions while it was not detectable in KRT-
19-nodules (data not shown). As expected, KRT-19 expression was readily detected in 
early HCCs, which are characterized by positivity for KRT-19 (Fig.5B). Co-localization 
analysis of the NEFL and KRT-19 proteins at cellular level revealed that only a small 
number of hepatocytes co-expresses the two proteins (Fig. 5A,B). 
 
Fig. 5 Immunofluorescence analysis for NEFL and KRT-19 protein expression in frozen sections of 
A) KRT-19+ pre-neoplastic lesions and B) early HCCs. (original magnification 20X). Arrows  indicate 
few hepatocytes showing co-expression of NEFL and KRT-19 in both types of lesions.  
 
Overall these results showed that, in agreement with mRNA levels, NEFL protein is 
expressed only in preneoplastic lesions positive for KRT-19 and in eHCC.  
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NEFL expression is not present in fetal, neonatal and regenerating liver 
Since the presence of this neurofilament protein has never been described in the liver, we 
wished to investigate whether NEFL expression in the carcinogenic process could be the 
result of a re-acquisition of proteins expressed in the fetal/neonatal life and lost in adult, 
differentiated hepatocytes. To this aim, we evaluated the mRNA levels of NEFL in 4 liver 
samples of 19 days fetuses and 2-days pups compared to 2 normal liver, 3 HCC and 2 
normal rat brain samples as positive control. As shown in Fig.6A, almost undetectable 
levels of mRNA were observed in the liver of 19 days fetuses or 2-days pups; these results 
indicate that the NEFL gene is not expressed at significant levels in the liver at early 
developmental stages, and therefore that NEFL expression in the liver carcinogenic 
process cannot be view as the re-acquisition of a fetal/neonatal phenotype.  
It is well known that pre-neoplastic and neoplastic hepatocytes are characterized by a 
proliferative rate higher than that of normal hepatocytes. Therefore, we reasoned that 
the up-regulation of NEFL during liver carcinogenesis in the H-R model could merely 
reflect the increased proliferative activity of pre-neoplastic and neoplastic cells. To verify 
this hypothesis, we assessed NEFL expression in proliferating normal hepatocytes, i.e. in 
regenerating liver upon 2/3 partial hepatectomy (PH). To this aim F-344 rats were 
subjected to surgery and BrdU was administered to label dividing hepatocytes. The results 
showed that, in spite of the high number of hepatocytes entering into S phase at 24 hours 
after PH (data are expressed as mean ± SD in 2/3 PH 24h vs normal liver: 27.53±0.79 vs 
1.13±0.56), no significant difference in the expression levels of NEFL was observed in 
regenerating livers compared to controls (fig.6B).  
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Taken together, these results demonstrate the NEFL expression in the liver is a specific 
feature of cancer onset and development. 
 
 
Fig.6 A) Analysis of NEFL gene expression by qRT-PCR in rat liver at different developmental stages 
and in HCC. NEFL mRNA expression was assessed in normal rat liver (n=2), HCC (n=3), fetal (n=4), 
neonatal liver samples (n=4) and normal rat brain (n=2) as positive control. Rat β-actin was used 
as endogenous control. (mean log expression for NEFL in HCC vs rat brain vs fetal liver vs neonatal 
liver: 1.43±0.69 vs 3.61±0.00 vs 0.03±0.42 vs 0.05±0.30). Analysis of significance was done by One-
Way ANOVA (p<0.0001). (***p< 0.0001 normal liver vs rat brain; *p< 0.01 normal liver vs HCC; 
**p< 0.001 HCC vs rat brain, fetal liver; *p< 0.01 HCC vs neonatal liver). B) Analysis of NEFL mRNA 
expression by qRT-PCR in rat liver at 24 hours after 2/3 PH. The levels of expression are calculated 
as fold change between control liver (n=2) and liver at 24 hours after 2/3 PH (n=4). Rat β-actin 
was used as endogenous control. (data are expressed as mean± SD NEFL in 2/3 PH 24h vs control: 
2.34±1.7 vs 1±0.46). 
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Analysis of CpG Island methylation status of the NEFL gene 
Aberrant methylation of the NEFL gene promoter has been described in head and neck 
cancers (Chen B et al., 2012). Therefore we wished to determine whether changes in the 
methylation status of the CpG islands of the NEFL gene could be responsible for its up-
regulation in HCC development. To this aim, we performed pyrosequencing analysis on 5 
rat HCCs and 3 liver controls. As shown in Table3, very low levels of methylation of the 
CpG islands of NEFL were detected in the HCCs analyzed, (average rate of methylation in 
HCC vs controls was 4.9±1.47 vs 3.4±0.20), with no significant differences compared to 
controls (P=0.135). Thus, these results make very unlikely the possibility that up-
regulation of NEFL is the consequence of aberrant transcriptional activation due to 
hypomethylation of the NEFL gene promoter.  
 
 
 
 
Table3: 
Methylation 
frequency at 
specific CpG sites 
in the promoter 
of the NEFL gene. 
10 CpG sites 
were scored for 
methylation by 
pyrosequencing. 
3 age-matched 
control normal 
liver and 5 HCCs 
were analyzed. 
Average rates of 
methylation for 
each sample are 
indicated in bold 
character. 
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Investigation of the role of microRNA in NEFL up-regulation 
microRNAs have been shown to play a fundamental role in the control of gene expression 
(Calin GA et al, 2006), and play a major role in cancer development [Esquela-Kerscher and 
Siack, 2006; Melo SA, 2011]. Therefore, we investigated whether down-regulation of 
miRNAs targeting NEFL mRNA could be the cause of NEFL up-regulation in rat HCC 
development. In silico analysis of predicted microRNA targets indicated that NEFL has a 
binding site for miR-30 family members. Initially, we assessed the expression levels of two 
miRNAs predicted to target NEFL, namely miRNA 30d e miRNA 30e. Expression levels 
were evaluated by qRT-PCR analysis in a set of 9 KRT-19 positive preneoplastic lesions and 
4 aged-matched (10 weeks) controls, plus 3 extra normal liver controls at 14 months of 
age (Fig.7A). qRT-PCR analysis did not show any significant difference in the expression of 
miRNA 30d e miRNA 30e in the KRT-19+ lesions vs respective controls, indicating that the 
expression of these two miRNAs is not modified during the early phases of the 
hepatocarcinogenic process.  Next, we assessed, by qRT-PCR, the levels of expression of 
NEFL and miR-30e in parallel in the same set of 12 early HCCs, in order to directly 
evaluate the relationship between miR-30e levels and NEFL expression in the same 
sample (fig.7B). The results show that while NEFL is significant up-regulated in the early 
HCCs respect to control liver (n=3), no change in the NEFL-targeting microRNA miR-30e 
could be found, suggesting that miR-30e is not involved in the regulation of the 
expression of NEFL in early HCCs.   
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Fig.7 Assessment of miR-30d and miR-30e expression by qRT-PCR at different stages of the 
hepatocarcinogenesis process. A) miR-30d and miR-30e expression was assessed in KRT-19+ 
preneoplastic microdissected samples, age-matched controls and 14 months normal liver 
controls. Differences in expression were not statistically significant. Rat β-actin was used as 
endogenous control. B) NEFL (upper panel) and miR-30e (lower panel) expression was assessed by 
qRT-PCR in parallel in the same early HCCs. The levels of expression were calculated as fold 
change between 3 control liver and 12 eHCC samples. Rat β-actin was used as endogenous control 
for NEFL. U6 small nuclear RNA was used as endogenous control for miR-30e. 
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Analysis of NEFL expression in human HCC 
Although the mechanisms responsible for NEFL up-regulation observed in rat pre- and 
neoplastic lesions remain obscure, the finding that this gene is highly up-regulated in 
hepatocarcinogenesis may represent a relevant observation endowed with possible 
prognostic/diagnostic value. Therefore, we sought to determine whether the results 
obtained in the R-H model could be of translational value for human HCC. To this aim, 
NEFL mRNA levels were determined by qRT-PCR in 14 human HCCs. NEFL expression 
levels in HCCs were compared to NEFL expression in matched cirrhotic tissues (CE) 
(Fig.8A). The results showed that, although statistical significance was not reached due to 
the low number of samples and the degree of variability, a trend towards an increase of 
expression of NEFL in HCCs compared to matched non-cancerous cirrhotic tissues (CE) 
was clearly observed. Notably, similar to rat normal liver, NEFL mRNA levels were 
undetectable in a liver biopsy of a “healthy” patient (cycle threshold CT>40).  
Next, the prognostic value of NEFL expression in human HCCs was evaluated in a cohort 
of 54 patients (the characteristics of the HCC patients are described in TableI). When 
patients were divided into NEFL low- or high-expression groups based on the median 
expression level (Fig.8B), the analysis showed that the time of recurrence following 
surgery was significantly shortened in the high NEFL expression group compared to that 
of the low-expression group. Notably, the results were highly statistically significant         
(p = 0.031). 
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Fig.8  A) Analysis of NEFL gene expression in by qRT-PCR in HCC and matched cirrhotic tissue (CE). 
Human β-actin was used as endogenous control (p=0.21). Analysis of statistical significance was 
done by t Student’s test (p=0.21). (Data are expressed as mean ± standard deviation (SD) (mean 
expression for NEFL in HCC vs CE: 6.05±0.069 vs 1±0.01).  B) Kaplan-Meier plot showing time of 
recurrence relative to patients resected for HCC, divided into two groups based on the expression 
of NEFL mRNA. The blue curve is relative to patients not overexpressing NEFL, that relapse less. 
The green curve refers to patients overexpressing NEFL that recur more and in a short time. Log 
rank (Mantel-Cox) test p=0.031. 
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Table I. Characteristics of HCC patients analysed in this study 
Serial N. Gender Age Cause of liver disease (1) Focality (2) Size (3) AFP (4) Grading (5) 
1 M 60 HCV multi 1.3 252577 G4 
2 M 79 HBV multi 7.0 540 G4 
3 M 75 HCV multi 3 6363 G3 
4 M 70 HCV multi 2.3 46 G3 
5 M 59 HCV uni 5 86 G3 
6 M 65 HCV+Ethanol uni 3.0 20 G3 
7 M 78 HCV uni 3 9 G2 
8 M 79 HCV multi 10 7 G3 
9 M 70 HCV uni 4.0 35 G3 
10 M 59 HCV+HBV uni 7 500 G4 
11 M 65 HCV multi 6.5 167 G3 
12 F 65 HCV uni 3.0 3 G3 
13 M 75 HCV multi 7.0 9 G3 
14 M 72 HCV multi 3.4 18 G3 
15 M 76 HBV-Ab multi 5 10.000 G4 
16 M 65 HBV+Ethanol uni 3.0 5 G2 
17 M 74 HCV multi 3.5 2198 G3 
18 M 60 Ethanol uni 1.8 156 G4 
19 M 54 HBV uni 4 162 G2 
20 M 59 HCV multi 3.0 76 G2 
21 M 68 HCV multi 2.5 5 G2 
22 M 65 None Multi 3 48 G3 
23 M 71 HCV multi 4 96 G3 
24 M 74 None uni 11 78 G3 
25 M 69 HCV uni 10 390 G3 
26 F 59 HCV uni 6 7 G4 
27 M 75 None multi 15 6 G3 
28 F 81 Hcv Multi 10 3000 G4 
29 M 59 HCV Multi 8 56 G4 
30 F 70 HCV Uni 4.8 90 G1 
31 M 66 HCV Uni 5.5 223 G2 
32 M 70 HBV Uni 8.0 162 G3 
33 M 69 None Uni 3.8 8 G2 
34 M 53 HCV Multi 5.0 285 G4 
35 M 70 HBV Multi 4.5 23 G2 
36 M 78 HBV Uni 3 - G3 
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37 M 66 HCV Uni 5 - G3 
38 F 60 HCV Multi 4,5 445 G3 
39 F 73 None uni 5.5 2 G3 
40 M 71 HBV Multi 4.4 65 G4 
41 M 68 HCV Uni 3.6 7 G2 
42 M 60 HBV + HCV Multi 2.3 34 G2 
43 F 80 HCV Uni 5.0 76 G3 
44 F 53 HCV MULTI 4.0 60 G3 
45 M 55 HCV+alcol Uni 7 3 G3 
46 M 77 HBV-Ab uni 5.0 4 G3 
47 F 69 HCV Uni 4 77 G2 
48 M 74 HCV Uni 6 30 G4 
49 F 76 HBV Uni 2 47 G3 
50 F 71 HCV uni 2.0 276 G3 
51 M 54 HCV Multi 3 19 G3 
52 M 63 None Multi 4,5 6 G2 
53 M   Uni 6,5 - G3 
54 F 72 HCV Uni 3 6 G3 
1. Cause of underlying liver disease: HBV: Hepatitis B Virus; HCV: Hepatitis C Virus; Ethanol: History of 
ethanol abuse; HBV-Ab: presence of the antibodies against HBV; None: negative history for 
hepatitis virus infection and ethanol abuse. 
2. Focality: uni-or multifocality was assessed on the basis of imaging techniques previous to surgery 
and by means of intra-operative ultrasound. 
3. Size of the HCC nodule (in centimeters) used for RNA and protein extraction.  
4. AFP: alpha-feto-protein determination was made prior to surgery and is expressed in ng/mL.  
5. Grading of the HCC was assessed according to Edmondson and Steiner’s criteria. 
 
 
 
 
 
 
 
 
55 
 
DISCUSSION 
 
The role of the NEFL gene in cancer development and progression is still poorly 
understood. Studies regarding the role of the NEFL protein have been mostly focused to 
neurological diseases, such as Charcot–Marie–Tooth’s disease (CMT) (Mersiyanova IV et al, 
2000). The correlation between NEFL and cancer development is mostly due to the 
frequent observation of LOH for the NEFL locus in several neoplasms including breast, 
head and neck, prostate, lung, colon, urinary bladder cancers, and HCC (Li XQ et al., 2012; 
Coon et al., 2004; Macoska JA et al., 1995; Kurimoto F et al., 2001; Lerebours F et al., 1999; 
Knowles MA et al., 1993; Becker et al., 1996). In some cases, as in breast cancer, LOH at the 
NEFL locus is associated with increased malignancy, consistent with a tumor-suppressive 
role for the NEFL gene (Yaremko ML et al, 1996).  
In normal tissues, NEFL expression is restricted to neurons, where it encodes type IV 
intermediate filament heteropolymers, which  represent a major component of the 
neuronal cytoskeleton. Intriguingly, ectopic expression of NEFL has been reported for 
several malignancies, including head and neck and breast cancers (Chen B et al. 2012, Li XQ 
et al., 2012). The aberrant expression of NEFL in cancerous tissues that, in their normal 
counterpart, do not express this gene, is not fully understood. It may be speculated that it 
may have an active role in tumor development, or it may merely be part of an adaptive 
cytoprotective response that follows malignant transformation (Julien JP, 1999). It has 
been shown, in this respect, that tissue cells, when exposed to cumulative physical and 
chemical carcinogenic factors, change their expression profile to adapt to the new 
microenvironment (Kim MS, et al, 2006).  
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Our gene expression studies results, obtained by cDNA microarray and qRT-PCR, 
demonstrate that NEFL is not expressed in normal rat adult liver. This finding was 
confirmed at the protein level, by immunofluorescence staining. On the other hand, in 
agreement with evidence collected for other malignancies (Chen B et al. 2012, Li XQ et al., 
2012), NEFL expression was readily detected during the hepatocarcinogenic process in R-H 
model. Indeed, cDNA microarray analysis and qRT-PCR analysis showed that the 
expression of NEFL was strongly up-regulated at all stages of the multistep process of 
hepatocarcinogenesis, including the very early ones. In particular, NEFL mRNA was 
strongly up-regulated in KRT-19 positive preneoplastic lesions and in early HCCs.  
In agreement with mRNA levels, immunofluorescence studies identified the 
neurofilament only in the preneoplastic lesions positive for KRT-19 and in early HCCs.  
Since the NEFL gene is not expressed in healthy adult liver, we wished to investigate 
whether NEFL expression during the carcinogenic process in the R-H model could be the 
result of a re-acquisition of fetal/neonatal life status, a phenomenon commonly 
associated to cancer development and progression.  However, our results indicate that 
this is not the case, since almost undetectable levels of mRNA were observed in the liver 
of 19 days fetuses or 2 days pups. Next, we asked whether expression of NEFL in the 
hepatocarcinogenic process could merely be associated to the increased proliferative 
activity of preneoplastic and neoplastic hepatocytes, since normal hepatocytes are 
quiescent in healthy liver, where NEFL gene is silent. However, no NEFL up-regulation was 
observed in actively dividing hepatocytes in liver regeneration occurring following 
two/thirds partial hepatectomy (PH), suggesting that NEFL expression in the liver is a 
specific feature of cancer onset and development.  
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The mechanisms responsible for the ectopic expression of NEFL through the carcinogenic 
process in the R-H model are still unknown. Our results demonstrate that dysregulation of 
the NEFL promoter through CpG island hypomethylation, potentially leading to aberrant 
NEFL expression, is not involved in the regulation of NEFL expression in the R-H model. 
Likewise, we ruled out, as a potential mechanism leading to elevated mRNA levels of NEFL 
during hepatocarcinogenesis, the downregulation of some miRNAs predicted to target  
NEFL, since their levels are unmodified during HCC onset and progression in the R-H 
model.  
To assess the clinical significance of NEFL expression in human HCC patients, we 
determined NEFL mRNA levels in 14 HCC patients. The results showed that, similarly to 
what observed in the rat model, while NEFL expression was undetectable in normal 
human liver, it was readily detectable in HCCs and in matched cirrhotic liver. This 
demonstrates that aberrant expression of NEFL takes place at the onset and progression 
in human hepatocarcinogenesis, translating our findings to human pathology. 
Interestingly, although not statistically significant, a clear trend towards an up-regulation 
of NEFL in HCCs when compared to matched cirrhotic tissue was observed. Notably, when 
patients were divided into two groups, NEFL low- or high-expressors, based on the 
median expression level, the results showed that time of recurrence was significantly 
shortened in high-NEFL expression compared to low-NEFL expression group, thus 
demonstrating that NEFL expression levels are a predictive factor for HCC prognosis.  
These results are in contrast with findings reported for early breast cancer patients, 
where a low NEFL mRNA expression level was found to be a negative prognostic factor to 
predict disease-free survival of early-stage breast cancer patients, supporting a tumor-
suppressive role for NEFL (Li XQ et al, 2012).  
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Overall, the role of the NEFL gene in cancer development is unclear. Several reports 
suggest a potential role as tumor suppressor for this gene in malignancies, such as breast 
cancer (Li XQ et al, 2012) and head and neck cancer (Huang et al, 2013). However, our 
findings in the animal model and more specifically our findings in human HCC patients, 
where a low expression of NEFL is a positive prognostic factor, clear challenge this view 
and actually support an oncogenic role for NEFL in liver carcinogenesis.    
Further studies are required to identify the mechanism(s) involved in the aberrant 
expression of  NEFL in hepatocarcinogenesis and its role in HCC development. A better 
knowledge of the role of NEFL in HCC progression might hopefully provide a novel 
therapeutic target for HCC.  
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